Compare Abeona Therapeutics Inc (ABEO) vs Electronic Arts Inc. (EA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Electronic Arts Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while Electronic Arts Inc. trades at $205.36 (market cap $51.51B). The key difference: Electronic Arts Inc. is far larger — about 138× Abeona Therapeutics Inc's market cap, and Electronic Arts Inc. pays a 0.37% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | EA | |
|---|---|---|
Market Cap | $373.32M | $51.51B |
Sector | Health | Technology |
52-Week High | $7.23 | $205.45 |
52-Week Low | $4.17 | $147.79 |
Enterprise Value | $228.22M | $50.08B |
Dividend Yield | — | 0.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Electronic Arts (EA) trades at $205.44, up 0.11% on the day, with a bullish technical signal from moving averages and strong profitability metrics including a 78.97% gross margin. Recent news highlights a potential $55 billion acquisition by Saudi investors pending EU approval and the launch of new gaming titles and an advertising platform, indicating active business development.
The stock presents a mixed outlook with high valuation ratios (P/E of 58.46) posing a risk, but analyst consensus leans positive with no sell ratings. Key risks include earnings volatility, as seen in recent misses, and regulatory scrutiny over the acquisition. Upside potential hinges on successful game launches and the advertising initiative driving future growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Electronic Arts Inc.
EA is one of the world's largest third-party video game publishers and has transitioned from a console-based video game publisher to the one of the largest publishers on consoles, PC, and mobile. The firm owns number of large franchises, including Madden, FIFA, Battlefield, Apex Legends, Mass Effect, Dragon's Age, and Need for Speed.
Read more on EA →
